The FARE Clinical Network is expanding, and will now comprise 28 centers of excellence across the country. The FARE Clinical Network, dedicated to changing the face of food allergy care, is the only collaborative network of its kind. Five centers have recently joined the network, which now comprises 28 centers of excellence across the country.… Continue reading New Centers of Excellence Join the FARE Clinical Network
Younger brothers and sisters of peanut-allergic children are at higher risk for peanut sensitivity than children in general. However, a Canadian study published in the June 2016 issue of Allergy found that siblings whose peanut allergy tests were negative prior to introduction did not have an allergic response when they ate peanut for the first… Continue reading In Siblings, Peanut Tolerance Is Predicted by Negative Test Results Prior to Introduction
The introduction of peanuts to infants at risk for developing a peanut allergy does not have a negative impact on growth or nutrition, nor does it affect the duration of breastfeeding, according to new findings published online June 10 in the Journal of Allergy and Clinical Immunology. In this study, funded by the National Institute… Continue reading Researchers: Peanut Allergy Prevention Strategy Resulting from LEAP Study is Nutritionally Safe
FARE recently received the Eugene Washington Engagement Award from the Patient-Centered Outcomes Research Institute (PCORI). FARE’s two-year project, “Empowering Patient Partners and Key Stakeholders to Develop a Patient-Centric Food Allergy Research Program,” seeks to address an unmet need in the research field by forming a partnership of patients empowered to work with other key stakeholders… Continue reading Interested in Providing the Patient Perspective in Research?
Earlier this month, FARE staff members attended the annual scientific meeting of the American Academy of Allergy, Asthma & Immunology, where researchers presented a number of new abstracts. Of interest to the food allergy community, both Aimmune Therapeutics and DBV Technologies presented new findings during the session for late-breaking abstracts. Aimmune Therapeutics Aimmune reported data… Continue reading Report from AAAAI: Aimmune and DBV Technologies Present New Findings
As FARE has been reporting, a number of abstracts were presented at this past weekend’s annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI). Here, we present information on a few of the studies involving food allergy that were highlighted in press releases from AAAAI. Long-term Follow-Up of Oral Immunotherapy for Multiple… Continue reading Report from AAAAI: Multiple Allergen OIT Follow-up, Socioeconomic Disparities and Peanut Exposure in Common Places
Epinephrine should be prescribed for all patients at risk of experiencing a severe reaction (anaphylaxis). Epinephrine is the only medication that can reverse the symptoms of anaphylaxis. Recent findings from poster presentations given at the annual meeting of the American Academy of Allergy, Asthma & Immunology reiterate the importance of having this life-saving medication available and… Continue reading New Findings on Epinephrine Availability and Use in Schools